DOI: https://doi.org/10.22263/2312-4156.2018.5.28
Prudnikov A.R., Shchupakova A.N.
The role of cytokines in the diagnosis of unstable atherosclerotic plaque
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2018;17(5):28-42.
Abstract.
The article is devoted to the role of cytokines in the diagnosis of atherosclerotic plaque instability and prognosis of adverse cardiovascular events.
At this moment atherosclerosis is considered not only as a disease due to the impaired functioning of the lipid transport system, but also as a long-term, sluggish chronic inflammation of the vascular wall with stable periods and exacerbations of the process. The process of destabilization of atherosclerotic plaque, its rupture and formation of thrombotic masses is the result of the direct participation of the immune system, which leads to the development of acute coronary events.
The mechanisms of atherosclerosis initiation, atherosclerotic plaque destabilization, as well as various diagnostic methods and the role of cytokines in determining the unstable course of atherosclerotic process are considered. Prospects for the use of cytokines as predictors of repeated cardiovascular events are outlined.
Key words: cytokines, plaque destabilization, diagnosing.
References
1. Belarus ranks sixth in mortality from cardiovascular diseases in the world [Elektronnyi resurs]. Thinktanks.by: [sait belorus. issled.]. 2017. Rezhim dostupa: https://thinktanks.by/publication/2017/05/21/belarus-na-shestom-meste-po-smertnosti-ot-serdechno-sosudistyh-zabolevaniy-v-mire.html. Data dostupa: 06.08.2018. (In Russ.)
2. Shalenkova MA, Mukhametova ET, Mikhaylova ZD. The role of markers of necrosis and inflammation in predicting acute forms of coronary heart disease. Klin Mmeditsina. 2013;91(11):14-20. (In Russ.)
3. Libby P. Inflammation in Atherosclerosis. Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2045-51. doi: http://dx.doi.org/10.1161/ATVBAHA.108.179705
4. Zykov MV, Barbarash OL, Kashtalap VV, Veremeev AV, Barbarash LS. Clinical and prognostic significance of interleukin-12 in patients with myocardial infarction. Med Immunologiia. 2011;13(2-3)219-26. (In Russ.)
5. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis. 2000 Jun;181 Suppl 3:S402-10. doi: http://dx.doi.org/10.1086/315596
6. Nikitskaya EA, Grivel' Zh-Sh, Maryukhnich EV, Lebedeva AM, Ivanova OI, Savvinova PP, i dr. Cytomegalovirus in plasma of patients with acute coronary syndrome. Acta Nature. 2016;8(2):114-9. (In Russ.)
7. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012 Jul;33(13):1635-701. doi: http://dx.doi.org/10.1093/eurheartj/ehs092
8. Avaliani VM, Popov VA, Martynov SI. New views on the mechanism of atherosclerosis development (literature review). Ekologiia Cheloveka. 2005;(4):24-30. (In Russ.)
9. Talaeva TV, Gavrish AS, Bratus' VV. Significance and mechanisms of inflammation as an independent factor of atherogenesis. Ukraїn Kardіol Zhurn. 2014;(4):49-69. (In Russ.)
10. Bekler A, Gazi E, Yılmaz M, Temiz A, Altun B, Barutçu A, et al. Could elevated platelet-lymphocyte ratio predict left ventricular systolic dysfunction in patients with non-ST elevated acute coronary syndrome? Anatol J Cardiol. 2015 May;15(5):385-90. doi: http://dx.doi.org/10.5152/akd.2014.5434
11. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989 Apr;79(4):733-43.
12. Aymagambetova AO. Atherogenesis and inflammation. Nauka Zdravookhranenie. 2016;(1):24-39. (In Russ.)
13. Karagodin VP, Bobryshev YuV, Orekhov AN. Inflammation, immunocompetent cells, cytokines - role in atherogenesis. Patogenez. 2014;12(1):21-35. (In Russ.)
14. Flego D, Liuzzo G, Weyand CM, Crea F. Adaptive Immunity Dysregulation in Acute Coronary Syndromes: From Cellular and Molecular Basis to Clinical Implications. J Am Coll Cardiol. 2016 Nov;68(19):2107-2117. doi: http://dx.doi.org/10.1016/j.jacc.2016.08.036
15. Tagieva NR, Shakhnovich RM, Mironov VM, Ruda MYa. Invasive methods for detection of unstable atherosclerotic plaques in coronary arteries. Kardiologiia. 2014;54(11):46-56. (In Russ.)
16. Tagieva NR, Shakhnovich RM, Veselova TN. Noninvasive methods for detection of unstable atherosclerotic plaques in coronary arteries. Kardiologiia. 2015;55(5):80-8. (In Russ.)
17. McDermott MM. Ankle-brachial index screening to improve health outcomes: Where is the evidence? Ann Intern Med. 2013;159(5):362-3. doi: http://dx.doi.org/10.7326/0003-4819-159-5-201309030-00012
18. Mishchenko TS, Pesotskaya EV. Thickening of the intima-media complex of the internal carotid artery as a predictor of ischemic stroke [Elektronnyi resurs]. Novosti Meditsiny Farmatsii. 2008;(2). Rezhim dostupa: HTTP://WWW.MIF-UA.COM/ARCHIVE/ARTICLE/4374. Data dostupa: 05.08.2018. (In Russ.)
19. Baldassarre D, Amato M, Bondioli A, Sirtori CR, Tremoli E. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. Stroke. 2000 Oct;31(10):2426-30.
20. Eleid MF, Lester SJ, Wiedenbeck TL, Patel SD, Appleton CP, Nelson MR, et al. Carotid ultrasound identifies high risk subclinical atherosclerosis in adults with low framingham risk scores. J Am Soc Echocardiogr. 2010 Aug;23(8):802-8. doi: http://dx.doi.org/10.1016/j.echo.2010.06.003
21. Danilova MA, Baydina TV. The role of serum cytokines in the pathogenesis of carotid atherosclerosis. Vrach-aspirant. 2011;(3.1):163-9. (In Russ.)
22. Fushtey IM, Podsevakhina SL, Tkachenko OV, Palamarchuk AI. Immunological aspects of endothelial dysfunction development in patients with coronary heart disease and determination of the role of risk factors in their formation. Vnutren Meditsina. 2007;(4):16-24. (In Russ.)
23. Loria V, Leo M, Biasillo G, Dato I, Biasucci LM. Biomarkers in Acute Coronary Syndrome. Biomarker Insights. 2008;3:453-68.
24. Sever PS, Poulter NR, Chang CL, Hingorani A, Thom SA, Hughes AD, et al. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2012 Feb;33(4):486-94. doi: http://dx.doi.org/10.1093/eurheartj/ehr262
25. Kopitsa NP, Litvin EI. Interleukin-10 and C-reactive protein as predictive markers of recurrent vascular events after acute coronary syndrome. Vestn Khar'k Nats Un-ta im VN Karazina Ser Meditsina. 2010;(19):42-6. (In Russ.)
26. Ponomar' EG, Syrkin AL, Gusev DE, Andreev DA. Markers of inflammation and long-term prognosis in patients with acute coronary syndrome and stable ischemic heart disease. Kardiologiia Serdechno-sosudistaia Khirurgiia. 2011;(6):10-5. (In Russ.)
27. de Lemos JA, Peacock WF, McCullough PA. Natriuretic peptides in the prognosis and management of acute coronary syndrome. Rev Cardiovasc Med. 2010;11 Suppl 2:S24-34.
28. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009 Dec;120(22):2177-87. doi: http://dx.doi.org/10.1161/CIRCULATIONAHA.109.884866
29. Springer J, Azer J, Hua R, Robbins C, Adamczyk A, McBoyle S, et al. The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors. J Mol Cell Cardiol. 2012 May;52(5):1122-34. doi: http://dx.doi.org/10.1016/j.yjmcc.2012.01.018
30. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families / B. Beutler, C. van Huffel. Science. 1994 Apr;264(5159):667-8.
31. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006 Apr;86(2):515-81. doi: http://dx.doi.org/10.1152/physrev.00024.2005
32. Simbirtsev AS. Cytokines: classification and biological functions. Tsitokiny Vvospalenie. 2004;3(2):16-22. (In Russ.)
33. Kukharchuk VV, Zykov KA, Masenko VP, Nuraliev EYu, Shakhnovich RM, Yarovaya EB. Dynamics of inflammatory process in patients with acute coronary syndrome and patients with stable angina. Biochemical and immunological aspects. Kardiol Vestn. 2007;2(2):48-5. (In Russ.)
34. Fatkhullina AR, Peshkova IO, Koltsova EK. The Role of Cytokines in the Development of Atherosclerosis. Biochemistry (Mosc). 2016 Nov;81(11):1358-1370. doi: http://dx.doi.org/10.1134/S0006297916110134
35. Crossman DC, Morton AC, Gunn JP, Greenwood JP, Hall AS, Fox KA, et al. Investigation of the effect of Interleukin-1 receptor antagonist (IL-1RA) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study). Trials. 2008 Feb;9:8. doi: http://dx.doi.org/10.1186/1745-6215-9-8
36. Kozlov VK. Cytokine therapy: pathogenetic direction in infectious diseases and clinical effectiveness: ruk dlia vrachei. Saint-Petersburg, RF: Al'ter Ego; 2010. 148 р. (In Russ.)
37. Belyuk SN, Snezhitskiy VA. The role of immune activation and systemic inflammation in the pathogenesis of chronic heart failure and treatment approaches. Zhurn GrGMU. 2010;(4):32-5. (In Russ.)
38. Zorin NA, Podkhomutnikov VM, Yankin MYu, Zorina VN, Arkhipova SV, Ryabicheva TG. Acute phase reactants of inflammation and interleukin-8 in myocardial infarction. Klin Lab Diagnostika. 2009;(4):36-7. (In Russ.)
39. Berns SA, Kiprina ES, Shmidt EA, Veremeev AV, Barbarash OL. Dynamics of changes in cytokine levels at the hospital stage in patients with different clinical variants of acute coronary syndrome. Med Immunologiia. 2016;18(1):33-40. (In Russ.)
40. Couper KN, Blount DG, Riley EM. Blount IL-10: the master regulator of immunity to infection. J Immunol. 2008 May;180(9):5771-7.
41. Mälarstig A, Eriksson P, Hamsten A, Lindahl B, Wallentin L, Siegbahn A. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart. 2008 Jun;94(6):724-9. Epub 2007 Aug 9. doi: http://dx.doi.org/10.1136/hrt.2007.119271
42. Kozlov VA, Dushkin MI, Vereshchagin EI. Vaccines against atherosclerosis: state of the problem and prospects for its development. Tsitokiny Vospalenie. 2008;7(1):9-14. (In Russ.)
43. Taleb S, Tedgui A, Mallat Z. Interleukin-17: friend or foe in atherosclerosis. Curr Opin Lipidol. 2010 Oct;21(5):404-8. doi: http://dx.doi.org/10.1097/MOL.0b013e32833dc7f9
44. Korzhenevskaya KV, Gavrisheva NA, Panov AV, Ses' TP, Alugishvili MZ, Kozlov VV. Transforming growth factor-β1 in different course of coronary heart disease after coronary bypass surgery. Med Immunologiia. 2010;12(6):521-8. (In Russ.)
45. Lutskiy AA, Zhirkov AA, Lobzin DYu, Rao M, Alekseeva LA, Meyrer M, i dr. Interferon-γ: biological function and significance for the diagnosis of cellular immune response. Zhurn Infektologii. 2015;7(4):10-22. (In Russ.)
46. Turmova EP, Markelova EV, Silaev AA, Luk'yanov PA, Chikalovets IV. Features of cytokine status in patients with atherosclerosis. Med Immunologiia. 2014;16(4):323-32. (In Russ.)
47. Makoveeva EA. The atherogenic index as an integral indicator of the destruction of the target organ (the heart) and hypertension [Elektronnyi resurs]. Universum: Meditsina i farmakologiia: elektron nauch zhurn. 2013;(1). Rezhim dostupa: http://7universum.com/ru/med/archive/item/322. Data dostupa: 06.09.2018. (In Russ.)
48. Gruzdeva OV, Akbasheva OE, Matveeva VG, Dyleva YuA, Palicheva EI, Karetnikova VN, i dr. Cytokine profile in visceral obesity and unfavorable prognosis of heart attack. Med Iimmunologiia. 2015;17(3):211-20. (In Russ.)
49. Chalikias GK, Tziakas DN, Kaski JC, Hatzinikolaou EI, Stakos DA, Tentes IK, et al. Interleukin-18:Interleukin-10 ratio and in-hospital events in patients with acute coronary syndrome. Atherosclerosis. 2005 Sep;182(1):135-43. doi: http://dx.doi.org/10.1016/j.atherosclerosis.2005.02.002
50. Aref'yeva TI, Balakhonova TV, Krasnikova TL, Noeva EA, Potekhina AV, Provatorov SI, Pylaeva EA, Ruleva NYu; FGBU RKNPK MZ RF, zaiavitel' i patentoobladatel'. A method for diagnosing predisposition to atherosclerosis progression in patients with chronic coronary heart disease by the content of interleukin-10-producing t-lymphocytes in peripheral blood: pat. 2575791 Ros Federatsiia: MPK G01N33/50. № 2014141098/15; zaiavl 13.10.14; opubl 20.02.16. (In Russ.)
Information about authors:
Prudnikov A.R. – Master of Medical Sciences, postgraduate of the Chair of Internal Medicine, Vitebsk State Order of Peoples’ Friendship Medical University;
Shchupakova A.N. – Doctor of Medical Sciences, professor of the Chair of Internal Medicine, pro-rector for treatment-and-pharmaceutical work and post-diploma education, Vitebsk State Order of Peoples’ Friendship Medical University.
Correspondence address: Republic of Belarus, 210009, Vitebsk, 27 Frunze ave., Vitebsk State Order of Peoples’ Friendship Medical University, Chair of Internal Medicine. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Alexander R. Prudnikov.
